US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,345.76

+24.191.83%

Number of Gainers:2

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,357.18

Open:1,347.70

Low:1,336.48

Close:1,321.57

Loading ...

Gilead Sciences (GILD) Gets a Buy from Mizuho Securities

Biotech Alert: Searches spiking for these stocks today

Top Midday Gainers

MT Newswires Live

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Novartis to Acquire Regulus in $1.7B Deal

Novartis to Acquire Regulus Therapeutics

MT Newswires Live

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit

MT Newswires Live

U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors

THOMSON REUTERS

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors

Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress

Simply Wall St.

Novartis reports Q1 core EPS $2.28, consensus $2.11

Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States

ACCESS Newswire

Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk

Novartis Surprises With Another Beat & Raise -- Market Talk

Sui Ecosystem Token Continues Bullish Trend, DEEP Surges Over 12.99% in 24 Hours

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Sui Ecosystem Token Continues to Surge, WAL Surges Over 16% in 24 Hours

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4578/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1345.7642,"timestamp":1746215999999,"preClose":1321.5748,"halted":0,"volume":9241330,"delay":0,"changeRate":0.018303,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":24.189331,"latestTime":"05-02 16:00:00 EDT","open":1347.704,"high":1357.1796,"low":1336.4781,"amount":968699197.233112,"amplitude":0.015664,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.104359,"peRate":18.860207,"turnoverRate":0.003021,"increases":2,"decrements":1,"flats":0,"marketCap":355022688696,"floatMarketCap":335368900736},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1357.1796,"amplitude":0.015664,"preClose":1321.5748,"low":1336.4781,"pbRate":"6.104359","latestPrice":1345.7642,"volume":9241330,"delay":0,"open":1347.704,"prevYearClose":1164.883,"prevWeekClose":1327.2651,"prevMonthClose":1353.2946,"prevQuarterClose":1364.0579,"fiveDayClose":1327.2651,"twentyDayClose":1371.8842,"sixtyDayClose":1292.9265,"secType":"PLATE","market":"US","turnoverRate":0.003021,"peRate":18.860207,"marketCap":355022688696,"floatMarketCap":335368900736,"timestamp":1746215999999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":2,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532878051","title":"Gilead Sciences (GILD) Gets a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2532878051","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532878051?lang=en_us&edition=fundamental","pubTime":"2025-05-03 02:15","pubTimestamp":1746209714,"startTime":"0","endTime":"0","summary":"In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-buy-from-mizuho-securities-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-buy-from-mizuho-securities-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","GILD","BK4568","LU1066053197.SGD","LU1585245621.USD","IE00B19Z3581.USD","LU2468319806.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU1571399168.USD","IE00B19Z3B42.SGD","MFG","LU0320765992.SGD","BK4139","IE00B3T34201.USD","LU0109394709.USD","BK4583","LU1066051498.USD","LU2087621335.USD","BK4532","BK4550","IE0002270589.USD","BK4588","LU0289739699.SGD","BK4566","BK4578","LU2089984988.USD","BK4585","IE00B7SZLL34.SGD","BK4207","IE00BSNM7G36.USD","LU1430594728.SGD","LU1839511570.USD"],"gpt_icon":0},{"id":"2532000582","title":"Biotech Alert: Searches spiking for these stocks today","url":"https://stock-news.laohu8.com/highlight/detail?id=2532000582","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532000582?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:15","pubTimestamp":1746116123,"startTime":"0","endTime":"0","summary":"These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:. Discover companies with rock-solid fundamentals in  TipRanks' Smart Value Newsletter.Receive undervalued stocks, resilient to market uncertainty,  delivered straight to your inbox.Tevogen Bio Holdings , 332% surge in interest. Pipeline and key clinical candidates for these companies:. Galmed is a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. The company has focused almost exclusively on developing Aramchol for the treatment of noncirrhotic nonalcoholic steatohepatitis, or NASH, and are currently developing Aramchol for Primary Sclerosing Cholangitis, or PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease.CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biotech-alert-searches-spiking-stocks-161523387.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-alert-searches-spiking-stocks-161523387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","TVGNW","IE00BJT1NW94.SGD","BCDAW","BK4578","SWTX","IE00B2B36J28.USD","BK4139","BK4588","TVGN","CMMB","NVS","IE0002141913.USD","BK4539","LU0320765489.SGD","BK4585","RGLS","LU0211331839.USD","IE0009355771.USD","LU0208291251.USD","IE00BJJMRZ35.SGD","BCDA","MKKGY","LU0070302665.USD","IE00B4R5TH58.HKD","BK4532","SNTI","CGON","GLMD","BK4007"],"gpt_icon":0},{"id":"2532615980","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2532615980","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532615980?lang=en_us&edition=fundamental","pubTime":"2025-05-01 01:47","pubTimestamp":1746035266,"startTime":"0","endTime":"0","summary":"Novartis  has agreed to acquire Regulus Therapeutics  for an initial payment of $7.00 per share in cash at closing, or $800 million, Regulus said Wednesday.Shares of Regulus more than doubled as intraday trading volume soared to over 23.4 million from a daily average of about 1.3 million.Oddity Tech  reported Q1 adjusted earnings and sales late Tuesday above forecasts and raised its full-year EPS and revenue guidance.Shares soared 26% as intraday trading volume surged to more than 4.2 million from a daily average of about 458,000.Jeffs' Brands  said Wednesday that it signed a definitive agreement to sell its Smart Repair Pro unit and its 49.1% stake in SciSparc Nutraceuticals to Plantify Foods.Shares jumped 52% as intraday trading volume catapulted to over 85.8 million compared with a daily average of about 317,000.Price: 113.49, Change: +0.04, Percent Change: +0.04","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJJMRZ35.SGD","BK4220","IE00B4R5TH58.HKD","JFBR","IE00BJT1NW94.SGD","BK4183","IE00B2B36J28.USD","RGLS","BK4532","BK4578","BK4588","BK4122","IE00BFTCPJ56.SGD","BK4585","IE0002141913.USD","IE0009355771.USD","LU0320765489.SGD","ODD","BK4139","LU0211331839.USD","LU0070302665.USD","LU0208291251.USD","BK4007","NVS"],"gpt_icon":0},{"id":"2532068105","title":"Regulus Shares Surge on $1.7 Billion Acquisition by Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2532068105","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532068105?lang=en_us&edition=fundamental","pubTime":"2025-05-01 00:20","pubTimestamp":1746030000,"startTime":"0","endTime":"0","summary":"Shares of Regulus Therapeutics more than doubled after the company agreed to be acquired by Novartis in a deal with an equity value of up to $1.7 billion.The stock was changing hands at $7.78 in midday trading after closing at $3.37 Tuesday. Shares have risen nearly fivefold since 2025 started and haven't traded this high in more than three years.The biopharmaceutical company, which specializes in medicines targeting microRNAs, said Wednesday that Novartis would initiate a tender offer to buy outstanding shares for $7 apiece, plus a non-tradeable contingent value right for another $7 a share once Regulus meets a certain regulatory milestone related to its farabursen treatment.Once the tender offer is complete, Regulus will merge with a subsidiary of Novartis and any remaining Regulus shares will be canceled and converted into the right to receive merger consideration.The deal is set to close in the second half of the year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","NVS","LU0320765489.SGD","BK4139","IE00BJT1NW94.SGD","IE0009355771.USD","BK4007","BK4588","BK4585","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0070302665.USD","LU0208291251.USD","IE00B4R5TH58.HKD","RGLS","BK4532","IE00B2B36J28.USD","LU0211331839.USD","BK4578"],"gpt_icon":0},{"id":"2532806847","title":"Why Novartis (NVS) is a Top Value Stock for the Long-Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2532806847","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532806847?lang=en_us&edition=fundamental","pubTime":"2025-04-30 21:40","pubTimestamp":1746020407,"startTime":"0","endTime":"0","summary":"It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.Why Investors Should Pay Attention to This Value Stock. Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.Many value investors pay close attention to a company's earnings as well. For NVS, four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.10 to $8.55 per share for 2025. Per share NVS boasts an avera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-novartis-nvs-top-value-134007183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE0002141913.USD","BK4578","NVS","BK4007","BK4588","IE00B4R5TH58.HKD","LU0208291251.USD","BK4532","IE0009355771.USD","LU0070302665.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0211331839.USD","LU0320765489.SGD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2531036583","title":"Novartis to Acquire Regulus in $1.7B Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2531036583","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531036583?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:39","pubTimestamp":1746013140,"startTime":"0","endTime":"0","summary":"Novartis has agreed to acquire Regulus Therapeutics for a total equity value of up to roughly $1.7 billion.With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus, the companies said Wednesday.Shares of Regulus, a San Diego biopharmaceutical company specializing in medicines targeting microRNAs, rocketed 135% to $7.90 in premarket trading Wednesday. The stock had already more than doubled in value this year as of Tuesday's close.The deal is set to close in the second half of the year, the companies said.Novartis will initiate a tender offer to acquire all of Regulus's shares for $7 apiece, plus a non-tradeable contingent value right for another $7 a share that will be payable once Regulus meets a certain milestone for getting regulatory approval for farabursen.Once the offer is complete, a subsidiary of Novartis will be merged with Regulus and any remaining Regulus shares will be cancelled and converte","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","RGLS","IE0002141913.USD","BK4007","BK4532","LU0070302665.USD","IE00BFTCPJ56.SGD","BK4585","IE00B4R5TH58.HKD","BK4588","BK4139","LU0208291251.USD","IE00BJT1NW94.SGD","LU0211331839.USD","BK4578","IE00B2B36J28.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD"],"gpt_icon":0},{"id":"2531478033","title":"Novartis to Acquire Regulus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2531478033","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531478033?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:22","pubTimestamp":1746012128,"startTime":"0","endTime":"0","summary":"Novartis to Acquire Regulus Therapeutics","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVS","RGLS","IE0002141913.USD","BK4007","BK4532","LU0070302665.USD","IE00BFTCPJ56.SGD","BK4585","IE00B4R5TH58.HKD","BK4588","BK4139","LU0208291251.USD","IE00BJT1NW94.SGD","LU0211331839.USD","BK4578","IE00B2B36J28.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD"],"gpt_icon":0},{"id":"2531033942","title":"Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2531033942","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531033942?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:10","pubTimestamp":1746011400,"startTime":"0","endTime":"0","summary":"Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease , a severe renal disease. Lead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that recently completed a Phase 1b multiple-ascending dose clinical trial. Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded  clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus’ lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease . The agreed deal is fully in line with the therapeutic area focus of Novartis and leverages our strength and expertise in renal disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-acquire-regulus-therapeutics-farabursen-111000881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0208291251.USD","PC","LU0070302665.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","BK4139","NVS","BK4578","IE0009355771.USD","BK4585","LU0211331839.USD","BK4532","IE00BJJMRZ35.SGD","BK4007","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4209","BK4588","RGLS","IE0002141913.USD"],"gpt_icon":0},{"id":"2531710023","title":"Gilead Sciences to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2531710023","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531710023?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:05","pubTimestamp":1745957100,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., April 29, 2025----Gilead Sciences, Inc.  announced today that its executives will be speaking at the following investor conferences:. BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM Pacific Time. RBC Capital Markets Global Healthcare Conference on Wednesday, May 21 at 11:30 AM Eastern Time. Bernstein Annual Strategic Decisions Conference on Thursday, May 29 at 2:30 PM Eastern Time. Jefferies Global Healthcare Conference on Wednesday, June 4 at 11:05 AM Eastern Time. Goldman Sachs Annual Global Healthcare Conference on Tuesday, June 10 at 11:20 AM Eastern Time. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-present-upcoming-investor-200500133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4568","BK4532","LU1571399168.USD","IE00B3T34201.USD","LU0109394709.USD","LU0289739699.SGD","IE00B19Z3581.USD","IE00BKVL7J92.USD","BK4588","LU0320765992.SGD","IE00B7SZLL34.SGD","LU1585245621.USD","BK4578","LU1066053197.SGD","GILD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","LU2468319806.SGD","LU2089984988.USD","BK4585","LU1066051498.USD","LU1839511570.USD","BK4583","LU0889565916.HKD","LU0058720904.USD","IE0002270589.USD","LU0234570918.USD","LU1430594728.SGD","BK4566","LU2087621335.USD","BK4550"],"gpt_icon":0},{"id":"2531767764","title":"Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2531767764","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531767764?lang=en_us&edition=fundamental","pubTime":"2025-04-30 02:19","pubTimestamp":1745950748,"startTime":"0","endTime":"0","summary":"Gilead Sciences  has agreed to pay $202 million in the settlement of a civil fraud lawsuit accusing it of paying kickbacks to healthcare practitioners to promote its HIV treatment drugs, the US Attorney for the Southern District of New York said in a Tuesday statement.The illegal kickbacks caused false claims for Gilead's HIV drugs to be paid by federal healthcare programs, in violation of the False Claims Act, according to the statement.Under the settlement, Gilead agreed to pay a total sum of $202 million, of which around $176.9 million will be paid to the US and the remainder will be paid to various states.  As part of the settlement, the company also made extensive factual admissions regarding its conduct, the statement said.The settlement was approved Monday by US District Judge Paul Engelmayer.Gilead did not immediately reply to a request for comment from MT Newswires.Price: 106.17, Change: -0.17, Percent Change: -0.16","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","BK4585","LU1585245621.USD","LU1571399168.USD","IE00B19Z3B42.SGD","BK4566","IE00B3T34201.USD","IE00B7SZLL34.SGD","BK4588","BK4532","LU2468319806.SGD","LU1430594728.SGD","LU2089984988.USD","LU1839511570.USD","LU0109394709.USD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","BK4568","IE0002270589.USD","BK4550","LU2087621335.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","BK4583","LU1066053197.SGD","LU0289739699.SGD","GILD","BK4139","BK4578","LU0320765992.SGD","LU1066051498.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"2531764556","title":"U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531764556?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:29","pubTimestamp":1745947786,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL1N3R7145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1430594728.SGD","LU1585245621.USD","LU0889565916.HKD","LU0058720904.USD","BK4588","LU2087621335.USD","BK4532","BK4568","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU0234570918.USD","IE00B19Z3581.USD","LU0289739699.SGD","LU0109394709.USD","IE00BZ1G4Q59.USD","GILD","LU2089984988.USD","LU1571399168.USD","BK4585","LU1066053197.SGD","IE00B3T34201.USD","BK4566","IE0002270589.USD","LU1839511570.USD","IE00BKVL7J92.USD","BK4578","IE00B7SZLL34.SGD","BK4550","LU2468319806.SGD","LU0320765992.SGD","BK4139","BK4583","LU1066051498.USD"],"gpt_icon":0},{"id":"2531764206","title":"Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764206","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531764206?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:29","pubTimestamp":1745947786,"startTime":"0","endTime":"0","summary":"Gilead Sciences reaches $202 million settlement with US over kickbacks to doctorsNEW YORK, April 29 (Reuters) - Gilead Sciences GILD.O has reached a $202 million settlement to resolve a civil fraud la","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL1N3R7145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","BK4568","BK4578","LU0109394709.USD","LU2089984988.USD","LU0234570918.USD","LU1839511570.USD","LU2468319806.SGD","LU0889565916.HKD","BK4588","BK4550","LU0058720904.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","LU2087621335.USD","BK4585","LU1066051498.USD","LU0320765992.SGD","LU1430594728.SGD","LU1066053197.SGD","BK4139","IE0002270589.USD","GILD","IE00B7SZLL34.SGD","LU1571399168.USD","BK4566","IE00B3T34201.USD","BK4532","IE00BZ1G4Q59.USD","LU1585245621.USD","BK4583"],"gpt_icon":0},{"id":"2531789793","title":"Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2531789793","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531789793?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:27","pubTimestamp":1745947636,"startTime":"0","endTime":"0","summary":"Gilead Sciences recently announced a presentation at the EASL Congress focusing on liver disease, with promising research in both hepatitis B and C. This comes alongside solid Q1 earnings results where a significant net income turnaround was noted. These developments, combined with a quarterly dividend declaration and ongoing share buybacks, potentially supported a 13% share price increase over the last quarter. Meanwhile, the general market showed strength with a 7% rise, suggesting Gilead's performance aligns with broader positive trends, further buoyed by robust earnings reports across various industries.We've identified 2 possible red flags with Gilead Sciences and understanding the impact should be part of your investment process.NasdaqGS:GILD Revenue & Expenses Breakdown as at Apr 2025. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-nasdaqgs-gild-showcases-172716096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00BKVL7J92.USD","LU1066053197.SGD","LU1066051498.USD","BK4568","BK4566","IE00B3T34201.USD","IE00BSNM7G36.USD","LU2089984988.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","BK4583","LU1839511570.USD","IE0002270589.USD","BK4532","BK4578","IE00B19Z3B42.SGD","LU1430594728.SGD","BK4588","IE00B7SZLL34.SGD","GILD","BK4585","LU0234570918.USD","LU0889565916.HKD","LU2468319806.SGD","LU2087621335.USD","LU1571399168.USD","LU0058720904.USD","LU0289739699.SGD","LU0320765992.SGD","LU1585245621.USD","BK4550","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2531375103","title":"Novartis reports Q1 core EPS $2.28, consensus $2.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2531375103","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531375103?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:50","pubTimestamp":1745938234,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $13.23B, consensus $13.02B. Commenting on Q1 results, Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis has had a strong st...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-reports-q1-core-eps-2-28-consensus-2-11?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-reports-q1-core-eps-2-28-consensus-2-11?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0211331839.USD","LU0208291251.USD","LU0320765489.SGD","IE00B2B36J28.USD","NVS","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4578","BK4585","BK4588","IE0009355771.USD","BK4007","LU0070302665.USD","BK4532"],"gpt_icon":0},{"id":"2531775351","title":"Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2531775351","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531775351?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:35","pubTimestamp":1745930100,"startTime":"0","endTime":"0","summary":"NORTHAMPTON, MA / ACCESS Newswire / April 29, 2025 / Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch AIDSVu - an online mapping tool that visualizes granular data related to the HIV epidemic in the United States.The tool was designed to help increase awareness and understanding of the impact of HIV across the U.S., especially in the South.AIDSVu analyses have revealed that although new HIV diagnoses have been declining throughout the country from 2008 to 2022, this progress has been uneven across regions. For example, the U.S. South saw only a 17% decrease in new HIV diagnoses during this period compared to a 43% decrease in the Northeast.\"Data is power,\" he says. \"Whether you are a mathematical person or a visual person, you can come and look and we can have a common understanding of what the HIV epidemic looks like in our city, in our ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-aidsvu-online-mapping-123500779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BZ1G4Q59.USD","BK4211","LU0058720904.USD","IE0002270589.USD","IE00B19Z3581.USD","LU0109394709.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","BK4550","BK4588","LU0234570918.USD","LU1430594728.SGD","LU1066053197.SGD","LU2468319806.SGD","LU0320765992.SGD","BK4583","BK4585","LU2087621335.USD","LU1571399168.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","IE00BSNM7G36.USD","LU1585245621.USD","BK4566","LU1839511570.USD","LU0889565916.HKD","BK4139","BK4578","BK4532","LU1066051498.USD","GILD","IE00BKVL7J92.USD","BK4568","LU2089984988.USD","UBCP"],"gpt_icon":0},{"id":"2531782972","title":"Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2531782972","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531782972?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:47","pubTimestamp":1745927220,"startTime":"0","endTime":"0","summary":"1147 GMT - Novartis's 2025 guidance lift for both sales and profits should be well-received among investors, Jefferies analysts say in a note. The Swiss drugmaker's higher revenue, a better gross margin and lower R&D spend drove its core operating income above consensus, the analysts say. \"We believe we could see a continuing beat-and-raise story this year,\" they say. Shares rise 0.7% to 94.04 euros.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4532","BK4578","BK4588","BK4211","IE00BFTCPJ56.SGD","BK4585","IE0002141913.USD","IE0009355771.USD","LU0320765489.SGD","LU0211331839.USD","ISBC","LU0070302665.USD","LU0208291251.USD","BK4007","NVS"],"gpt_icon":0},{"id":"2531783542","title":"Novartis Surprises With Another Beat & Raise -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2531783542","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531783542?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:42","pubTimestamp":1745923320,"startTime":"0","endTime":"0","summary":"1042 GMT - Novartis exceeded expectations with profit and sales figures, accompanied by an improved outlook, defying concerns about upcoming generic competition in the U.S. for three of its key products, Vontobel analyst Stefan Schneider says in a note. \"With the generic entry to three Novartis products still expected per mid-year, the guidance increase appears to us as a very confident sign that the company's growth drivers are expected to perform well also during the remainder of the year,\" he says. The Swiss drugmaker hereby signals that it can comfortably overcompensate the expected generic erosion, he says. Shares rise 1.1% to 94.43 euros. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B2B36J28.USD","LU0208291251.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0211331839.USD","BK4585","BK4007","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0070302665.USD","IE0002141913.USD","BK4578","BK4532","NVS"],"gpt_icon":0},{"id":"2531212982","title":"Sui Ecosystem Token Continues Bullish Trend, DEEP Surges Over 12.99% in 24 Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2531212982","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531212982?lang=en_us&edition=fundamental","pubTime":"2025-04-29 10:21","pubTimestamp":1745893260,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 29, according to GMGN market data, the Sui ecosystem's native tokens continued to surge, including:DEEP currently has a market capitalization of $6.95 billion, with a 24-hour increase of 12.99%;BLUE currently has a market capitalization of $39.5 million, with a 24-hour increase of 10.8%;NAVX currently has a market capitalization of $4.5 million, with a 24-hour increase of 7.29%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/291635","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BLUE","BK4578","BK4556","DEEP","BK4139"],"gpt_icon":0},{"id":"2531608266","title":"Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2531608266","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531608266?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 28, 2025----Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company’s executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company’s Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/contineum-therapeutics-appoints-timothy-watkins-200500814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GILD","LU0289739699.SGD","BK4532","BK4583","SQQQ","BK4007","LU1571399168.USD",".IXIC","MNQmain","BK4139","USAW.SI","LU0320765992.SGD","IE00BKVL7J92.USD","LU1585245621.USD","LU1066053197.SGD","LU2087621335.USD","LU2089984988.USD","LU1430594728.SGD","BK4585","QLD","BK4588","IE00B7SZLL34.SGD","NVIW.SI","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","TSYW.SI","QID","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4578","LU1839511570.USD","CTNM","LU0109394709.USD","NQmain","LU0058720904.USD","TQQQ","BK4568","LU2468319806.SGD","USJW.SI","IE0002270589.USD","PSQ","LU1066051498.USD","BK4566","LENZ","BK4550","LU0889565916.HKD","IE00B3T34201.USD","LU0234570918.USD"],"gpt_icon":1},{"id":"2530907164","title":"Sui Ecosystem Token Continues to Surge, WAL Surges Over 16% in 24 Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2530907164","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530907164?lang=en_us&edition=fundamental","pubTime":"2025-04-28 10:56","pubTimestamp":1745808960,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 28th, according to market data, the Sui ecosystem token continues to rise, including:WAL surged over 16% in the past 24 hours, now trading at $0.63;DEEP surged over 15% in the past 24 hours, now trading at $0.1996;BLUE surged over 13% in the past 24 hours, now trading at $0.1225;TURBOS surged over 9.5% in the past 24 hours, now trading at $0.00194.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/291484","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4211","WAL","LU0106831901.USD","BLUE","DEEP","LU1668664300.SGD","BK4139","BK4578","BK4585","BK4589","BK4588","BK4556","LU1791807156.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}]}}